When Juno Therapeutics launched in 2013, cell therapy was a nascent field. Early clinical studies were showing dramatic rates of remissions in leukemia patients treated with their own immune cells,… Read More
At home and at work, Justine Dell’Aringa is up for a challenge. The scientific associate director of Translational Research for Bristol Myers Squibb’s Immuno-Oncology and Cell Therapy Thematic Research Center… Read More
Seattle’s Fred Hutchinson Cancer Research Center has found its next leader, announcing Tuesday that Dr. Thomas J. Lynch Jr. will become the institution’s new president and director. Lynch is a well-known… Read More
The $74 billion merger of Bristol-Myers Squibb and Celgene has been delayed as FTC pushback spurred Celgene to divest a major psoriasis drug. The news rattled investors’ confidence and sent… Read More
Henrik Andersen, head of biologics development at Bristol-Myers Squibb, knows what it’s like to be at a hot biotech when it’s scooped up by a much larger player. Andersen was… Read More
Things are a little on edge in Seattle’s biotech scene after the Jan. 3 announcement that pharmaceutical giant Bristol-Myers Squibb (BMS) intends to buy Celgene, the parent company of Juno… Read More